Hager Biosciences, LLC is a preclinical-stage drug discovery organization based on innovative medicinal chemistry capabilities. Hager seeks to become a preferred partner to pharmaceutical and biotech firms by providing therapeutic leads through out-licensing for unmet medical needs. Central to the business model is Hager's capability to design and synthesize proprietary small fragment molecules for modular adaptation into new or existing drug candidate optimization programs. Hager's discovery FragPhoreTM platform provides a competitive advantage for rapid medicinal chemistry optimization and drug rescue via profile/properties improvement, as well as modular fragments for intellectual property enhancement. Hager's focus is on Chronic & Neuropathic Pain; Substance Abuse & Addiction; Metabolic Disorders; and Infectious Diseases
